Winslow Evans & Crocker Cut Acceleron Pharma (XLRN) Position By $3.28 Million; Akre Capital Management Has Lowered Enstar Group Limited (ESGR) Holding By $8.84 Million

June 3, 2018 - By Louis Casey

Enstar Group Limited (NASDAQ:ESGR) Logo

Akre Capital Management Llc decreased Enstar Group Limited (ESGR) stake by 2.91% reported in 2018Q1 SEC filing. Akre Capital Management Llc sold 42,112 shares as Enstar Group Limited (ESGR)’s stock rose 4.05%. The Akre Capital Management Llc holds 1.40M shares with $295.38M value, down from 1.45 million last quarter. Enstar Group Limited now has $4.38B valuation. The stock increased 0.42% or $0.85 during the last trading session, reaching $204.1. About 21,340 shares traded. Enstar Group Limited (NASDAQ:ESGR) has risen 8.82% since June 3, 2017 and is uptrending. It has underperformed by 3.75% the S&P500.

Winslow Evans & Crocker Inc decreased Acceleron Pharma Inc (XLRN) stake by 4.94% reported in 2018Q1 SEC filing. Winslow Evans & Crocker Inc sold 84 shares as Acceleron Pharma Inc (XLRN)’s stock declined 18.55%. The Winslow Evans & Crocker Inc holds 1,616 shares with $63.15 million value, down from 1,700 last quarter. Acceleron Pharma Inc now has $1.64B valuation. The stock increased 0.93% or $0.33 during the last trading session, reaching $35.87. About 363,575 shares traded or 22.28% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since June 3, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

More important recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron Pharma’s (XLRN) CEO Habib Dable on Q1 2018 Results – Earnings Call Transcript” on May 14, 2018, also Benzinga.com published article titled: “SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion”, Pehub.com published: “VC-backed Prevail Therapeutics beefs up board with new addition” on May 25, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) was released by: Investingnews.com and their article: “Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension” with publication date: May 22, 2018.

Investors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It improved, as 13 investors sold XLRN shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. Citadel Advisors Ltd stated it has 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Metropolitan Life Insur New York has 12,234 shares for 0% of their portfolio. Manufacturers Life Insur The has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Us State Bank De holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 500 shares. Artisan Prns Ltd Partnership holds 0.03% or 352,286 shares in its portfolio. Congress Asset Mgmt Ma owns 15,488 shares. Quantitative Invest Mngmt Ltd Liability Corp accumulated 13,700 shares. Waddell And Reed holds 28,300 shares or 0% of its portfolio. 3,246 are owned by Pub Employees Retirement Association Of Colorado. Eventide Asset Mngmt Ltd holds 529,900 shares. Credit Suisse Ag stated it has 51,468 shares or 0% of all its holdings. Bank Of America De has 57,195 shares for 0% of their portfolio. Proshare Advsr holds 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 25,799 shares. Voya Investment Mngmt Ltd Com owns 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 16,011 shares. Alps has invested 0.02% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Winslow Evans & Crocker Inc increased Blackstone Group LP (NYSE:BX) stake by 174 shares to 1,850 valued at $59.11 million in 2018Q1. It also upped Stratasys Ltd (NASDAQ:SSYS) stake by 130 shares and now owns 180 shares. Vanguard Group (VIG) was raised too.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on August, 2. They expect $-0.64 EPS, up 16.88% or $0.13 from last year’s $-0.77 per share. After $-0.58 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 10.34% negative EPS growth.

Since December 15, 2017, it had 0 buys, and 13 selling transactions for $7.84 million activity. Another trade for 4,300 shares valued at $182,363 was sold by Kumar Ravindra. Sherman Matthew L also sold $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shares. Another trade for 105,122 shares valued at $3.76 million was made by George Jean on Friday, December 15. MCLAUGHLIN KEVIN F also sold $814,848 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shares. 1,204 shares valued at $46,232 were sold by Quisel John D on Tuesday, April 3. Shares for $1.55 million were sold by POPS RICHARD F on Tuesday, March 6. On Tuesday, January 2 the insider Rovaldi Christopher sold $96,134.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Acceleron Pharma had 41 analyst reports since August 13, 2015 according to SRatingsIntel. Barclays Capital maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Wednesday, September 20 with “Overweight” rating. The firm earned “Neutral” rating on Thursday, December 17 by Janney Capital. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, February 28. Citigroup maintained the stock with “Buy” rating in Thursday, March 1 report. The stock has “Market Perform” rating by Oppenheimer on Tuesday, June 13. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Buy” rating given on Thursday, June 1 by Oppenheimer. RBC Capital Markets maintained the shares of XLRN in report on Thursday, November 2 with “Hold” rating. The firm has “Hold” rating given on Tuesday, August 1 by Oppenheimer. The firm has “Outperform” rating by Oppenheimer given on Friday, November 20. The stock has “Buy” rating by H.C. Wainwright on Monday, January 8.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: